AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
Key Financial Performance
Revenue for the quarter $35 million, a 17.8% decline versus the prior year quarter. The decline is attributed to a 15.2% decrease in cases to 2,780 and a 3% decline in average revenue per case to $12,587.
Same-store revenue Down approximately 22% year-over-year. This reflects a decrease in same-store cases by approximately 20%.
Cost of services Decreased by $2.9 million compared to the prior year period, but as a percentage of revenue, it increased to 42.5% from 41.8%.
Selling, general and administrative expenses Decreased by $6 million compared to the same period in fiscal 2024. This reflects cost management activities and reductions in equity-based compensation.
Customer acquisition cost Approximately $3,100 per case, up from $2,900 in the prior year quarter.
Adjusted EBITDA $3 million, down from $4.7 million in the prior year quarter. Adjusted EBITDA margin was 8.7%, down from 11% in the prior year quarter. The decline is due to revenue decreases.
Net loss for the quarter $9.5 million. Adjusted net loss was $2.4 million or $0.04 per diluted share.
Noncash impairment charge $4.6 million related to the Salesforce technology project, as certain components will not be used.
Loss related to London facility closure Approximately $2.3 million, primarily due to impairment of long-term assets. Additionally, $1 million was recorded in selling, general and administrative expenses for accelerated amortization of the right-of-use asset.
Revenue at London center $400,000 for the quarter, with an adjusted EBITDA of negative $150,000. For the 9 months ended September 30, 2025, revenue was $1.4 million with an adjusted EBITDA of negative $600,000.
Cash flow from operations A use of $225,000 compared to an increase of $1.8 million in the third quarter of 2024.
Cash and gross debt As of September 30, 2025, cash was $5.4 million and gross debt outstanding was $57.9 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Introduction of new services: AirSculpt is introducing new services to capture the GLP-1 market opportunity, including skin tightening procedures and additional treatments for loose skin. These services are complementary to their core body contouring business and aim to address the side effects of GLP-1 medications.
GLP-1 market opportunity: The company is targeting the growing demand for aesthetic procedures among GLP-1 patients, with 63% of these patients seeking treatments post-use. This represents a significant new consumer base for AirSculpt.
Cost management: Year-to-date, AirSculpt has achieved over $3 million in annualized cost savings, net of investments in new growth initiatives.
Debt reduction: The company has repaid nearly $18 million of debt year-to-date, focusing on strengthening its balance sheet.
Closure of London center: AirSculpt closed its unprofitable London center to focus resources on North American locations, which show greater growth potential.
Sales and marketing strategy: The company is enhancing its marketing approach with a diversified media mix, including influencer campaigns and TV advertising, to improve lead quality and conversion rates. It is also implementing new training modules and tools for its sales team.
Capital allocation: AirSculpt is prioritizing debt repayment and investing in growth initiatives, including new procedures, to drive long-term growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Third quarter revenue was $35 million, a 17.8% decline compared to the prior year, with same-store revenue down approximately 22%. This decline impacts financial performance and operational stability.
Case Volume Decline: Cases declined 15.2% to 2,780, with same-store cases down approximately 20%. This indicates reduced customer demand, which could affect revenue and operational efficiency.
London Center Closure: The decision to close the London center, which was the only unprofitable location, resulted in a $2.3 million loss and reflects challenges in international market expansion.
Salesforce Project Impairment: A $4.6 million noncash impairment charge was recorded due to the partial failure of the Salesforce technology project, indicating inefficiencies in technology investments.
Customer Acquisition Costs: Customer acquisition cost increased to $3,100 per case from $2,900 in the prior year, reflecting higher marketing expenses and potential inefficiencies in lead generation.
Debt Levels: Gross debt outstanding was $57.9 million, with a leverage ratio of 3.04x. While debt repayment is ongoing, high leverage could limit financial flexibility.
Revenue Guidance Reduction: 2025 revenue guidance was reduced to $153 million from the previous range of $160 million to $170 million, reflecting lower-than-expected performance.
GLP-1 Market Risks: While the GLP-1 market presents opportunities, the company noted that many clients require procedures beyond skin tightening, which could increase operational complexity and costs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook for 2025: The company has updated its revenue outlook to approximately $153 million, down from the previous guidance range of $160 million to $170 million.
Adjusted EBITDA Guidance for 2025: The company is reiterating the low end of its adjusted EBITDA guidance at approximately $16 million, within the range of $16 million to $18 million.
Fourth Quarter Revenue and EBITDA Expectations: The company expects a smaller year-over-year revenue decline in Q4 and improving same-store sales performance compared to the year-to-date trend. Implied Q4 EBITDA guidance highlights stronger margins, both sequentially and year-over-year.
Long-term Growth Opportunity in GLP-1 Market: The company is focusing on capturing the GLP-1 market opportunity, which is expected to drive significant long-term growth. New procedures addressing loose skin and skin tightening are being introduced, with GLP-1 therapies reshaping the aesthetics landscape.
Marketing and Sales Strategy Enhancements: The company is adapting its marketing spend to align with revenue trends, focusing on higher conversion rates, targeted influencer campaigns, and television advertising. New training modules and tools are being implemented for the sales team.
Capital Allocation and Debt Repayment: The company has repaid nearly $18 million of debt year-to-date and continues to prioritize debt repayment in the near term. Investments in growth initiatives, including new procedures, will continue.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the cost-cutting measures taken and their sustainability into the fourth quarter and next year?
A:Dennis Dean explained that cost controls have primarily focused on SG&A and regional support positions. While some measures were taken in the cost of services, the main focus remains on SG&A. The company continues to identify additional opportunities for cost savings and expects these measures to sustain into the fourth quarter and beyond.
Q:Can you elaborate on the progress with the stand-alone skin tightening service and plans for new services targeting the GLP-1 population?
A:Yogesh Jashnani stated that while there is demand for skin tightening, the pool of qualified candidates was smaller than expected due to the severity of loose skin. The company is piloting skin excisions and has seen good demand even without marketing. These procedures take 3-6 months for full results, and marketing will expand once results are available. The company is also exploring a suite of procedures to address the GLP-1 population.
Q:What caused the timing issue in Q3, and how is the company addressing it?
A:Yogesh Jashnani attributed the timing issue to a challenging consumer environment, with hesitancy in converting interest into purchases. Despite strong leads and consultations, short-term revenue was lower than expected. However, Q4 same-store sales trends are improving, and the company is focusing on the broader GLP-1 opportunity, which shows better conversion rates than non-GLP-1 users.
Q:What is the surgeon interest and capability for skin excision procedures, and will there be changes in marketing for the GLP-1 opportunity?
A:Yogesh Jashnani confirmed strong surgeon interest and capability for skin excisions, with many surgeons already experienced in such procedures. Marketing and sales strategies will adapt to target GLP-1 users effectively, focusing on messaging, targeting, and addressing issues like loose skin and uneven fat deposits.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numerical data or detailed timelines for the sustainability of cost savings and the expansion of new services. Additionally, while they acknowledged the smaller-than-expected pool for skin tightening and the broader GLP-1 opportunity, they did not provide clear metrics or detailed plans for addressing these challenges.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AirSculpt base
AirSculpt capability
AirSculpt context
AirSculpt potential
AirSculpt summary
America location
CFO position
GLP medication
GLP opportunity
GLP patient
ICR
allocation term
area focus
area margin
area service
body contouring
capital allocation
change
date
discipline area
improvement capital
margin improvement
marketing discipline
opportunity sale
procedure skin
sale marketing
scale brand
service GLP
side effect
term procedure
trajectory
transition
use
weight loss
AIRS Transcript
AirSculpt Technologies, Inc. (AIRS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call highlights positive debt reduction and a strengthened balance sheet, but flat revenue growth and increased customer acquisition costs are concerns. The guidance for revenue and EBITDA shows modest growth expectations, and the Q&A indicates reliance on marketing strategies for improvement. The absence of new center openings and uncertainties in refinancing and macroeconomic conditions add risks. These mixed signals suggest a neutral stock price movement over the next two weeks.
AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
Unknown4-2
The earnings call reveals significant challenges: a 15% revenue decline, financial control issues, and a high debt level. Although there is some margin expansion and positive signs in body sculpting trends, the overall financial health is concerning. The Q&A section suggests cautious optimism for future revenue but lacks strong positive catalysts. Given these factors, the stock is likely to experience a negative reaction in the short term.
AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
AIRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
